Morgan Stanley
VNRX icon

Morgan Stanley’s VolitionRx Ltd VNRX Stock Holding History

Morgan Stanley’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42 Hold
31
– – ﹤0.01% 8143
2026
Q1 		$126 Sell
31
-2
-6% -$10 ﹤0.01% 7760
2025
Q4 		$170 Sell
33
-7
-18% -$53 ﹤0.01% 7648
2025
Q3 		$543 Hold
40
– – ﹤0.01% 7483
2025
Q2 		$608 Sell
40
-5
-11% -$55 ﹤0.01% 7410
2025
Q1 		$513 Sell
45
-500
-92% -$5.96K ﹤0.01% 7368
2024
Q4 		$6.54K Buy
545
+400
+276% +$5.37K ﹤0.01% 6934
2024
Q3 		$1.74K Sell
145
-4,316
-97% -$55.5K ﹤0.01% 7156
2024
Q2 		$54K Sell
4,461
-2,239
-33% -$32.8K ﹤0.01% 6143
2024
Q1 		$101K Sell
6,700
-6,873
-51% -$135K ﹤0.01% 5985
2023
Q4 		$195K Buy
13,573
+3,057
+29% +$44.9K ﹤0.01% 5961
2023
Q3 		$145K Sell
10,516
-394
-4% -$9.74K ﹤0.01% 5718
2023
Q2 		$303K Sell
10,910
-915
-8% -$30.1K ﹤0.01% 5462
2023
Q1 		$452K Sell
11,825
-770
-6% -$32.2K ﹤0.01% 5309
2022
Q4 		$612K Sell
12,595
-6,323
-33% -$246K ﹤0.01% 5134
2022
Q3 		$515K Sell
18,918
-944
-5% -$35.7K ﹤0.01% 5255
2022
Q2 		$815K Sell
19,862
-4,108
-17% -$207K ﹤0.01% 5152
2022
Q1 		$1.44M Buy
23,970
+492
+2% +$27.9K ﹤0.01% 4745
2021
Q4 		$1.48M Sell
23,478
-5,647
-19% -$385K ﹤0.01% 4801
2021
Q3 		$1.8M Sell
29,125
-1,334
-4% -$84.5K ﹤0.01% 4653
2021
Q2 		$2M Buy
30,459
+855
+3% +$57.9K ﹤0.01% 4628
2021
Q1 		$2.24M Buy
29,604
+5,015
+20% +$430K ﹤0.01% 4167
2020
Q4 		$1.91M Buy
24,589
+7,361
+43% +$507K ﹤0.01% 4193
2020
Q3 		$1.11M Buy
17,228
+1,710
+11% +$116K ﹤0.01% 4139
2020
Q2 		$1.21M Buy
15,518
+4,487
+41% +$324K ﹤0.01% 4025
2020
Q1 		$686K Buy
11,031
+995
+10% +$83K ﹤0.01% 4195
2019
Q4 		$951K Buy
10,036
+2,693
+37% +$279K ﹤0.01% 4569
2019
Q3 		$825K Buy
7,343
+2,625
+56% +$209K ﹤0.01% 4412
2019
Q2 		$296K Buy
4,718
+630
+15% +$40.8K ﹤0.01% 4852
2019
Q1 		$266K Sell
4,088
-25
-0.6% -$1.4K ﹤0.01% 4911
2018
Q4 		$149K Sell
4,113
-72
-2% -$3.43K ﹤0.01% 5405
2018
Q3 		$217K Sell
4,185
-25
-0.6% -$1.03K ﹤0.01% 5422
2018
Q2 		$168K Sell
4,210
-1,000
-19% -$44.7K ﹤0.01% 5592
2018
Q1 		$250K Buy
5,210
+2,040
+64% +$119K ﹤0.01% 5373
2017
Q4 		$186K Buy
3,170
+100
+3% +$5.85K ﹤0.01% 5440
2017
Q3 		$161K Buy
3,070
+125
+4% +$7.34K ﹤0.01% 5441
2017
Q2 		$209K Hold
2,945
– – ﹤0.01% 5306
2017
Q1 		$237K Sell
2,945
-50
-2% -$4.42K ﹤0.01% 5245
2016
Q4 		$274K Sell
2,995
-200
-6% -$17.9K ﹤0.01% 5223
2016
Q3 		$339K Buy
3,195
+600
+23% +$46.6K ﹤0.01% 4750
2016
Q2 		$163K Buy
2,595
+1,070
+70% +$73.8K ﹤0.01% 5034
2016
Q1 		$108K Sell
1,525
-25
-2% -$1.88K ﹤0.01% 5286
2015
Q4 		$140K Buy
1,550
+250
+19% +$21.2K ﹤0.01% 5244
2015
Q3 		$116K Buy
1,300
+725
+126% +$55.7K ﹤0.01% 5356
2015
Q2 		$46K Buy
575
+50
+10% +$3.78K ﹤0.01% 5883
2015
Q1 		$43K Buy
+525
New +$43.5K ﹤0.01% 5848

Other funds holding VNRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Morgan Stanley's VNRX Position: Q2 2026 in Review

Morgan Stanley held its VolitionRx Ltd (VNRX) position steady in Q2 2026 at 31 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #8143.

Morgan Stanley first reported a position in VNRX in Q1 2015 and has held it in 46 quarters since. The position peaked at $2.24M in Q1 2021. 22 funds tracked by Wall St. Rank hold VNRX as of Q2 2026.

  • Morgan Stanley held 31 shares of VolitionRx Ltd worth $42 as of Q2 2026.
  • Morgan Stanley left its VolitionRx Ltd share count unchanged in Q2 2026.
  • VolitionRx Ltd made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8143 holding.
  • Morgan Stanley first reported a position in VolitionRx Ltd in Q1 2015 and has held it in 46 quarters since.
  • Morgan Stanley's VolitionRx Ltd position peaked at $2.24M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.